443 related articles for article (PubMed ID: 29907424)
1. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Johnston TH; Lacoste AMB; Visanji NP; Lang AE; Fox SH; Brotchie JM
Neuropharmacology; 2019 Mar; 147():11-27. PubMed ID: 29907424
[TBL] [Abstract][Full Text] [Related]
2. Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia.
Johnston TH; Lacoste AMB; Ravenscroft P; Su J; Tamadon S; Seifi M; Lang AE; Fox SH; Brotchie JM; Visanji NP
Neuropharmacology; 2024 May; 248():109880. PubMed ID: 38412888
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
AlShimemeri S; Fox SH; Visanji NP
Expert Opin Emerg Drugs; 2020 Jun; 25(2):131-144. PubMed ID: 32366130
[TBL] [Abstract][Full Text] [Related]
4. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
Schaeffer E; Pilotto A; Berg D
CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for levodopa-induced dyskinesia.
Al Dakheel A; Beaulieu-Boire I; Fox SH
Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
[TBL] [Abstract][Full Text] [Related]
7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
8. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
[TBL] [Abstract][Full Text] [Related]
9. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
11. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
[TBL] [Abstract][Full Text] [Related]
12. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
13. CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity.
Parsons CG
Neuropharmacology; 2019 Mar; 147():4-10. PubMed ID: 30165077
[TBL] [Abstract][Full Text] [Related]
14. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
Ko WK; Li Q; Bezard E
Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
[TBL] [Abstract][Full Text] [Related]
15. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS
Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647
[TBL] [Abstract][Full Text] [Related]
16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
17. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
[TBL] [Abstract][Full Text] [Related]
18. Synaptic plasticity may underlie l-DOPA induced dyskinesia.
Borgkvist A; Lieberman OJ; Sulzer D
Curr Opin Neurobiol; 2018 Feb; 48():71-78. PubMed ID: 29125979
[TBL] [Abstract][Full Text] [Related]
19. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
[TBL] [Abstract][Full Text] [Related]
20. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
